Core Viewpoint - The report from CITIC Securities indicates that policy-driven standardization will contribute positively to the growth of the diversified payment system in the pharmaceutical industry, enhancing consumer awareness of commercial health insurance and providing additional growth opportunities for the sector [1] Group 1: Policy Impact - The gradual standardization of the industry through various policies is expected to improve the completeness of urban commercial health insurance products like Huiminbao, which will likely enhance residents' consumption awareness of commercial insurance [1] - The introduction of products such as Huiminbao and group insurance is anticipated to accelerate the incubation of related innovative business models [1] Group 2: Long-term Growth Prospects - The long-term outlook for the innovative pharmaceutical and medical device industry chain is positive, as the development of commercial insurance is expected to gradually remove restrictions, leading to significant improvements in payment and distribution channels [1] - This improvement is projected to provide additional market space for relevant companies in the innovative pharmaceutical and high-end medical sectors [1]